CytoSorbents Gains Significant Funding for Future Growth
CytoSorbents Corporation (NASDAQ: CTSO), a prominent player in the field of blood purification technologies, has recently secured approximately $1.7 million in non-dilutive funding through the New Jersey Business Tax Certificate Transfer Program, facilitated by the New Jersey Economic Development Authority (NJEDA). This financial boost is a critical part of the company’s ongoing strategy to enhance its cash reserves and support its ambitious growth initiatives.
Strategic Partnership with NJEDA
Peter J. Mariani, Chief Financial Officer of CytoSorbents, expressed appreciation for the partnership with NJEDA, stating that this collaboration allows the company to convert its unused Net Operating Losses (NOLs) and R&D tax credits into significant financial resources. This method not only strengthens the company’s financial position but also ensures that it can continue its important work in life-saving medical technologies. The funding is expected to aid in the preparations for the upcoming U.S. launch of DrugSorb™-ATR and expand the manufacturing capabilities at CytoSorbents' new facility.
Advancements in Blood Purification Technologies
CytoSorbents' innovative products are essential for treating severe medical conditions in critical care settings. The company specializes in technologies that utilize advanced blood purification methods to remove harmful substances from the bloodstream. This capability is particularly crucial during intensive medical procedures, such as cardiac surgeries, where managing blood thinners and toxins can mean the difference between life and death. Their flagship product, CytoSorb®, has gained traction and is utilized in numerous hospitals across various countries.
Impact of Recent Legislation
In March 2025, New Jersey enacted a tax reform bill that retroactively improved the tax landscape for businesses like CytoSorbents. This legislation enabled CytoSorbents to amend its tax returns, thereby increasing available NOLs for sale through the NJEDA program. Such legislative support significantly enhances the resources available to technology and biotechnology firms, enabling them to harness their innovations more effectively.
Future Outlook and Development Plans
The resources gained will bolster CytoSorbents’ efforts in manufacturing and expanding its product lines. The upcoming trials for DrugSorb™-ATR are set to reshape treatment protocols for high-risk surgical patients. This investigational device aims to manage bleeding complications more effectively for patients undergoing surgical procedures while on blood-thinning medications.
Commitment to Innovation
CytoSorbents' commitment to improve patient outcomes through innovation is unwavering. With several products in development and multiple patents granted, the company primes itself for growth in the medical technology landscape. Continuous advancements in their blood purification technologies position them at the forefront of the industry.
Frequently Asked Questions
What is CytoSorbents Corporation known for?
CytoSorbents Corporation specializes in blood purification technologies used to treat life-threatening conditions in critical care and cardiac surgery.
How did CytoSorbents secure funding?
The company secured $1.7 million through the New Jersey Business Tax Certificate Transfer Program, leveraging its unused Net Operating Losses and R&D tax credits.
What are the future plans for DrugSorb™-ATR?
DrugSorb™-ATR is set to undergo trials to help manage perioperative bleeding in high-risk surgical patients.
Where are CytoSorbents' technologies currently used?
The company’s technologies are utilized in hospitals across more than 70 countries, providing critical support in surgical procedures.
What impact will the tax reform legislation have on the company?
The recent tax reform legislation will allow CytoSorbents to enhance its tax advantages, enabling greater financial flexibility and innovation investment.
